3
Announcements
Trials
Browse
Landscape
Phase
Phase 2/3
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Plasma cell
1
Other hematologic neoplasm
1
Lymphoid
1
Conditions
Infections
9
Lymphoma
6
Neoplasms, Plasma Cell
5
Neoplasms
5
Leukemia
5
Multiple Myeloma
3
Lymphoma, Non-Hodgkin
3
Urinary Tract Infections
2
Prostatic Neoplasms
2
Waldenstrom Macroglobulinemia
1
Urinary Bladder Neoplasms
1
Thrombocythemia, Essential
1
Surgical Wound Infection
1
Skin Neoplasms
1
Sezary Syndrome
1
Sepsis
1
Primary Myelofibrosis
1
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
1
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
Polycythemia Vera
1
Pdgfra-Associated Chronic Eosinophilic Leukemia
1
Myeloproliferative Disorders
1
Myelodysplastic-Myeloproliferative Diseases
1
Myelodysplastic Syndromes
1
Mycosis Fungoides
1
Lymphoproliferative Disorders
1
Lymphoma, T-Cell, Cutaneous
1
Lymphoma, Mantle-Cell
1
Lymphoma, Large-Cell, Immunoblastic
1
Lymphoma, Large-Cell, Anaplastic
1
Interventions
Lenalidomide
2
ofatumumab
1
Trimethoprim, Sulfamethoxazole Drug Combination
1
SARS-CoV-2 inactivated vaccines
1
Influenza Vaccines
1
Immunoglobulins
1
Hizentra
1
Clavulanic Acid
1
Ciprofloxacin
1
Amoxicillin
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
OTHER
×
Agammaglobulinemia
×
Trimethoprim, Sulfamethoxazole Drug Combination
×
Clear all
NCT05678621
2024-04-19
RATIONALISE
Monash University
Phase 2/3
Recruiting
300 enrolled